Literature DB >> 25017139

G2019S LRRK2 mutant fibroblasts from Parkinson's disease patients show increased sensitivity to neurotoxin 1-methyl-4-phenylpyridinium dependent of autophagy.

Sokhna M S Yakhine-Diop1, José M Bravo-San Pedro1, Rubén Gómez-Sánchez1, Elisa Pizarro-Estrella1, Mario Rodríguez-Arribas1, Vicente Climent2, Ana Aiastui3, Adolfo López de Munain4, José M Fuentes5, Rosa A González-Polo6.   

Abstract

Parkinson's disease (PD) is a neurodegenerative disorder of unknown etiology. It is considered as a multifactorial disease dependent on environmental and genetic factors. Deregulation in cell degradation has been related with a significant increase in cell damage, becoming a target for studies on the PD etiology. In the present study, we have characterized the parkinsonian toxin 1-methyl-4-phenylpyridinium ion (MPP(+))-induced damage in fibroblasts from Parkinson's patients with the mutation G2019S in leucine-rich repeat kinase 2 protein (LRRK2) and control individuals without this mutation. The results reveal that MPP(+) induces mTOR-dependent autophagy in fibroblasts. Moreover, the effects of caspase-dependent cell death to MPP(+) were higher in cells with the G2019S LRRK2 mutation, which showed basal levels of autophagy due to the G2019S LRRK2 mutation (mTOR-independent). The inhibition of autophagy by 3-methyladenine (3-MA) treatment reduces these sensitivity differences between both cell types, however, the inhibition of autophagosome-lysosome fusion by bafilomycin A1 (Baf A1) increases these differences. This data confirm the importance of the combination of genetic and environmental factors in the PD etiology. Thereby, the sensitivity to the same damage may be different in function of a genetic predisposition, reason why individuals with certain mutations can develop some early-onset diseases, such as individuals with G2019S LRRK2 mutation and PD.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Autophagy; Cell death; LRRK2; Neurotoxin; Parkinson’s disease

Mesh:

Substances:

Year:  2014        PMID: 25017139     DOI: 10.1016/j.tox.2014.07.001

Source DB:  PubMed          Journal:  Toxicology        ISSN: 0300-483X            Impact factor:   4.221


  18 in total

1.  Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice.

Authors:  M Yue; K M Hinkle; P Davies; E Trushina; F C Fiesel; T A Christenson; A S Schroeder; L Zhang; E Bowles; B Behrouz; S J Lincoln; J E Beevers; A J Milnerwood; A Kurti; P J McLean; J D Fryer; W Springer; D W Dickson; M J Farrer; H L Melrose
Journal:  Neurobiol Dis       Date:  2015-03-31       Impact factor: 5.996

Review 2.  Autophagy in Parkinson's Disease.

Authors:  Xu Hou; Jens O Watzlawik; Fabienne C Fiesel; Wolfdieter Springer
Journal:  J Mol Biol       Date:  2020-02-13       Impact factor: 5.469

Review 3.  The function of orthologues of the human Parkinson's disease gene LRRK2 across species: implications for disease modelling in preclinical research.

Authors:  Rebekah G Langston; Iakov N Rudenko; Mark R Cookson
Journal:  Biochem J       Date:  2016-02-01       Impact factor: 3.857

4.  Aberrant epigenome in iPSC-derived dopaminergic neurons from Parkinson's disease patients.

Authors:  Rubén Fernández-Santiago; Iria Carballo-Carbajal; Giancarlo Castellano; Roger Torrent; Yvonne Richaud; Adriana Sánchez-Danés; Roser Vilarrasa-Blasi; Alex Sánchez-Pla; José Luis Mosquera; Jordi Soriano; José López-Barneo; Josep M Canals; Jordi Alberch; Ángel Raya; Miquel Vila; Antonella Consiglio; José I Martín-Subero; Mario Ezquerra; Eduardo Tolosa
Journal:  EMBO Mol Med       Date:  2015-12       Impact factor: 12.137

5.  Fibroblast Biomarkers of Sporadic Parkinson's Disease and LRRK2 Kinase Inhibition.

Authors:  G A Smith; J Jansson; E M Rocha; T Osborn; P J Hallett; O Isacson
Journal:  Mol Neurobiol       Date:  2015-09-23       Impact factor: 5.590

6.  Comparative mRNA Expression of eEF1A Isoforms and a PI3K/Akt/mTOR Pathway in a Cellular Model of Parkinson's Disease.

Authors:  Kawinthra Khwanraj; Suriyat Madlah; Khwanthana Grataitong; Permphan Dharmasaroja
Journal:  Parkinsons Dis       Date:  2016-02-14

7.  Impaired Mitophagy and Protein Acetylation Levels in Fibroblasts from Parkinson's Disease Patients.

Authors:  Sokhna M S Yakhine-Diop; Mireia Niso-Santano; Mario Rodríguez-Arribas; Rubén Gómez-Sánchez; Guadalupe Martínez-Chacón; Elisabet Uribe-Carretero; José A Navarro-García; Gema Ruiz-Hurtado; Ana Aiastui; J Mark Cooper; Adolfo López de Munaín; José M Bravo-San Pedro; Rosa A González-Polo; José M Fuentes
Journal:  Mol Neurobiol       Date:  2018-07-21       Impact factor: 5.590

8.  The parkinsonian LRRK2 R1441G mutation shows macroautophagy-mitophagy dysregulation concomitant with endoplasmic reticulum stress.

Authors:  Sokhna M S Yakhine-Diop; Mario Rodríguez-Arribas; Saray Canales-Cortés; Guadalupe Martínez-Chacón; Elisabet Uribe-Carretero; Mercedes Blanco-Benítez; Gema Duque-González; Marta Paredes-Barquero; Eva Alegre-Cortés; Vicente Climent; Ana Aiastui; Adolfo López de Munain; José M Bravo-San Pedro; Mireia Niso-Santano; José M Fuentes; Rosa A González-Polo
Journal:  Cell Biol Toxicol       Date:  2021-05-31       Impact factor: 6.819

Review 9.  Mitochondria: A Therapeutic Target for Parkinson's Disease?

Authors:  Yu Luo; Alan Hoffer; Barry Hoffer; Xin Qi
Journal:  Int J Mol Sci       Date:  2015-09-01       Impact factor: 5.923

Review 10.  Dysregulation of autophagy and mitochondrial function in Parkinson's disease.

Authors:  Bao Wang; Neeta Abraham; Guodong Gao; Qian Yang
Journal:  Transl Neurodegener       Date:  2016-10-31       Impact factor: 8.014

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.